You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news. We post this and all... Read more
A California Senate committee has effectively killed a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators. After moving through two other panels over the past month, the Senate Appropriations Committee declined to... Read more
The Biden administration’s announcement about its formal move to reschedule marijuana has elicited another round of applause from lawmakers, industry stakeholders and advocacy groups. While the Justice Department already confirmed two weeks ago that it would be moving to place cannabis in Schedule III, rather than Schedule I, of... Read more
Following considerable debate on the New Hampshire Senate floor on Thursday, state lawmakers have revised and approved a House-passed bill that would legalize marijuana in the state. The measure, which senators advanced on a 14–9 vote, next heads to the Finance Committee before returning again to the chamber floor... Read more
A GOP congresswoman says that while she supports the push to federally reschedule marijuana, she is warning a top Biden administration official to refrain from taking steps to more broadly decriminalize other drugs. At a hearing before the House Education and the Workforce Committee on Wednesday, Rep. Lori Chavez-DeRemer... Read more
German lawmakers are set to consider amendments to a marijuana legalization law that took effect last month, with committees of the nation’s parliament scheduled to begin debate on changes related to cannabis cultivation at social clubs and impaired driving this week. One of the proposals set to be taken... Read more
AYR Wellness Reports First Quarter 2024 Results Q1 Revenue up 3% Q/Q to $118.0 Million, Excluding Discontinued Operations Q1 GAAP Loss from Operations Improved to $2.0 Million, Excluding Discontinued Operations Q1 Adjusted EBITDA¹ up over 10% Y/Y to $29.1 Million, with Adjusted EBITDA Margin of 25% Company generated free... Read more
Cresco Labs Reports Continued Trend of Financial Improvement with First Quarter 2024 Financial Results Over 10x year-over-year increase in operating cash flow CHICAGO–(BUSINESS WIRE)– Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of... Read more
